Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup
Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...
Hosted on MSN20h
Stifel Initiates Coverage of Edgewise Therapeutics (EWTX) with Hold Recommendation
Fintel reports that on January 22, 2025, Stifel initiated coverage of Edgewise Therapeutics (NasdaqGS:EWTX) with a Hold ...
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Up 8.9% in December
Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during ...
Edgewise Therapeutics: Strategic Positioning and Promising Clinical Advancements Support Buy Rating
Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on EWTX stock, giving a Buy rating yesterday.Stay Ahead of the ...
Edgewise Therapeutics promotes Behrad Derakhshan to COO
Edgewise Therapeutics (EWTX) announced changes to its executive team. These changes include the addition of Robert Blaustein, joining the ...
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target
Stifel analysts began coverage of Edgewise Therapeutics (NASDAQ:EWTX), currently valued at $2.6 billion, with a Hold rating and set a price target of $30.00. According to InvestingPro data, the stock ...
Stockhouse10d
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
Ph.D., President and Chief Executive Officer of Edgewise Therapeutics. “Additionally, we are thrilled with initial results from EDG-7500 in patients with obstructive hypertrophic cardiomyopathy and ...
Business Wire10d
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
--(BUSINESS WIRE)--Edgewise Therapeutics ... with obstructive hypertrophic cardiomyopathy and look forward to sharing additional, longer-term data across HCM populations in 2025.” ...